Mr. Dean Burns reports

OCUMETICS ANNOUNCES PRIVATE PLACEMENT

Ocumetics Technology Corp. proposes to complete a non-brokered private placement of up to 3,125,000 units of the corporation at a price of 32 cents per unit for gross proceeds of up to $1-million. There will be no minimum subscription level for this offering. Each unit will consist of one common share in the share capital of the corporation and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional common share at an exercise price of 64 cents for a period of two years from the date of issuance of the warrant.

The corporation may pay finders' fees on all or a portion of the private placement to eligible persons seeking subscribers to the financing, all in accordance with applicable securities laws and the policies of the TSX Venture Exchange.

Assuming the maximum offering is completed, 100 per cent of the net proceeds are expected to be used to finance the corporation's first in-human clinical trials, expected to commence in Q1 2024, and for continuing research and development. Although the corporation intends to use the proceeds of the offering as described above, the actual allocation of proceeds may vary from the uses set out above, depending upon future operations, events or opportunities.

About Ocumetics Technology Corp.

Ocumetics is a Canadian research and product development company that specializes in adaptive lens designs. Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry. Ocumetics has developed an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near.

We seek Safe Harbor.